Growth hormone deficiency following radiotherapy for orbital and parameningeal sarcomas.
Pediatr Hematol Oncol
; 16(1): 23-33, 1999.
Article
en En
| MEDLINE
| ID: mdl-9932270
Growth hormone deficiency (GHD) is a recognized late effect of successful treatment of tumors requiring cranial irradiation. Growth after treatment was assessed in 16 patients with sarcomas of the orbital and parameningeal regions. Median age at diagnosis was 6.35 years and median follow-up was 7.2 years. Treatment consisted of combination chemotherapy and radical radiotherapy, conventionally fractionated with a median dose 4500 cGy; the hypothalamic/pituitary region received a median dose of 4163 cGy. Height was measured every 6 months and 13/16 patients underwent tests of GH function. At GH testing median height standard deviation score (SDS) was -0.7, a median decrease of -0.55 since tumor diagnosis. Seven patients were treated with human GH (hGH) at a median of 3.7 years from tumor diagnosis and followed for a median of 2.7 years. Treatment with hGH resulted in a median increase in height SDS of 0.9. Careful surveillance with timely introduction of GH replacement is required for treatment of GHD following treatment of orbital and parameningeal sarcomas.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Radioterapia
/
Rabdomiosarcoma
/
Sarcoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Hormona de Crecimiento Humana
/
Neoplasias del Ojo
/
Trastornos del Crecimiento
/
Neoplasias Meníngeas
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Pediatr Hematol Oncol
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Año:
1999
Tipo del documento:
Article
Pais de publicación:
Reino Unido